This trial is evaluating whether Ruxolitinib will improve 1 primary outcome and 1 secondary outcome in patients with Ductal Carcinoma In Situ. Measurement will happen over the course of 15 days (+/- 5 days).
This trial requires 100 total participants across 2 different treatment groups
This trial involves 2 different treatments. Ruxolitinib is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Even if cure is sought for a precancerous condition, the risk of relapse is high, and survival is usually shortened. This warrants routine and regular follow-up of patients during their disease span." - Anonymous Online Contributor
"There is a lack of a standard treatment protocol developed for individuals with a pre-cancerous condition. We do not know who is most susceptible to certain risks related to treatment. What to expect from treatments for pre-cancerous conditions is dependent on the type of condition. We do not know how to address the psychosocial issues of people who are at risk of developing a pre-cancerous or cancer condition." - Anonymous Online Contributor
"As the number of cancers increases, there is a more obvious relationship seen in precancerous conditions. The relationship between the occurrence of precancerous conditions and the increase of cancer incidence is even stronger than the relationship between the occurrence of cancer and the increase in incidence of precancerous conditions." - Anonymous Online Contributor
"Many possible genetic factors exist for precancerous conditions and these are discussed with the relevant literature for the five conditions examined in this study. The possibility of the condition of precancerous condition in a non-cancerous process may be explained by the assumption that the condition is caused by a combination of genetic factors, some of which are the same as those involved in the cancers. Thus, most of the observed linkages between the conditions and cancers may be because some of the same genetic components are involved in both processes." - Anonymous Online Contributor
"We did not identify any national guideline or policy statement to guide clinicians who diagnose or treat patients with PC, even those patients who are at higher risk for developing PC. An update of the current national guidelines for PC is needed." - Anonymous Online Contributor
"It is the case that many people present with non-specific subjective symptoms that are suggestive of many systemic diseases, particularly those that involve immunosuppression. We suggest that when non-specific symptoms present with a substantial number of clinical contacts with healthcare professionals over long periods, an investigation for systemic disease should be initiated, not only to assess for specific cancer risk factors but also to detect precancerous conditions." - Anonymous Online Contributor
"[Precancers and cancer develop from early alterations in epithelial tissue architecture, cell turnover, and cell death that occur prior to the development of the first neoplastic neoplastic change from pre-malignant to malignant dysplastic and then carcinoma. The development of cancer is frequently associated with a pre-malignant condition or group of pre-malignant conditions that have common etiology(s) or pathologic manifestations and progression. For the purposes of this article, conditions are considered dysplastic if there exists a probability of neoplastic progression." - Anonymous Online Contributor
"Many side effects of ruxolitinib had a duration of <or= 3 months. Side effects included diarrhea, fatigue, nausea, anemia, neutropenia, constipation, vomiting, abnormal liver enzymes, and peripheral edema. There were no clinically significant changes in heart rate and blood pressure when ruxolitinib was used alone. Other adverse events occurring at a higher rate during the combination trials included fever (13.5% in combination and 5.9% in monotherapy trials), rash (9.7% in combination and 1.8% in monotherapy trials), hyponatremia (5% in combination and 4.2% in monotherapy trials), cough (3." - Anonymous Online Contributor
"People with precancerous conditions experience a range of discomfort. Although they are often reassured and satisfied at the initial consultation, over half of them develop symptoms. If symptoms are new, those with precancerous conditions should be encouraged to keep a diary of symptoms in order to identify a pattern." - Anonymous Online Contributor
"Twenty-six percent of ruxolitinib users were enrolled by their providers who were only using the drug in combination with some other drug, even though the drug could be administered alone. Ruxolitinib should be used alone or in combination with other treatments only when medically appropriate." - Anonymous Online Contributor
"There is a lot of research underway for the prevention and reversal (prevention only) of precancerous conditions. But there are many more things to learn that are of less clinical value, including the cause of cancer and other non-traditional risk factors. Please consider visiting the [Curse of precancerous conditions] page for the latest information on these conditions." - Anonymous Online Contributor
"In adults, ruxolitinib (100 mg twice daily and 600 mg once daily) was well tolerated across all dose levels tested in clinical trials, and the most common side effects in people (over 10% of people) were of mild to moderate severity. In clinical trials for people with myelofibrosis, only transient elevations of hepatic aminotransferase concentrations occurred; other blood lipid and blood chemistry abnormalities have not been reported in clinical trials with ruxolitinib." - Anonymous Online Contributor